Regard vs CoverMyMeds
Side-by-side comparison of AI visibility scores, market position, and capabilities
NYC healthcare AI clinical insights at $350M valuation Jul 2024 with 3M+ diagnoses surfaced and $50M+ incremental revenue for partners; $81.3M total ($61M Oak HC/FT Series B) serving Banner Health and Sentara competing with Nuance CDI.
About
Regard is a New York-based healthcare AI company — backed with $81.3 million in total funding including a $61 million Series B in July 2024 led by Oak HC/FT with Cedars-Sinai Health Ventures at a $350 million valuation, following a $15.3 million Series A in 2022 and $5 million seed in 2021 — providing health systems with an AI clinical insights platform that analyzes 100% of hospitalized patient medical record data to surface missed diagnoses to care teams, acting as an AI co-pilot for physicians that has surfaced 3 million+ diagnoses and generated $50+ million in incremental revenue for health system partners through improved documentation accuracy. Founded in 2019 by Eli Ben-Joseph, Nate Wilson, and Thomas Moulia (Stanford graduate students) and launched in 2021, Regard serves major health systems including Banner Health (33 acute care hospitals) and Sentara Health (12 hospitals).
Largest prior authorization network in the US connecting 75K+ pharmacies, 750K+ providers, and all payers. Columbus OH; acquired by McKesson; available free to providers and pharmacies; processes millions of PA requests annually for specialty and retail prescriptions at no provider cost.
About
CoverMyMeds is the largest prior authorization platform in the United States, operating a network that connects more than 750,000 providers, 75,000 pharmacies, and virtually all payers to streamline the authorization process for prescription medications. Founded in 2008 in Columbus, Ohio, and acquired by McKesson Corporation in 2017, CoverMyMeds processes millions of prior authorization requests annually and has become foundational infrastructure for the US pharmacy and specialty medication market. The platform is available at no cost to providers and pharmacies and is funded through health plan and PBM partnerships.\n\nCoverMyMeds' network effect is central to its value: because the platform is used by the vast majority of pharmacies and a very large share of prescribing providers, payers can reach their entire provider and pharmacy network through a single connection. The platform supports real-time benefit checks that show the formulary status and prior authorization requirements for a drug at the point of prescribing, enabling providers to make more informed prescribing decisions before a patient reaches the pharmacy counter. Automated electronic prior authorization (ePA) workflows reduce approval times from days to hours for eligible drug-payer combinations.\n\nAs part of McKesson, CoverMyMeds has expanded its capabilities to include specialty medication access solutions, patient assistance program enrollment, and medication adherence tools. The company's RxCrossroads subsidiary provides hub services for specialty pharmaceutical manufacturers, creating a comprehensive access ecosystem that spans from initial authorization through patient support and adherence management.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.